<DOC>
	<DOCNO>NCT01217177</DOCNO>
	<brief_summary>The cervix cancer second malignant neoplasia common woman . The combined treatment involve chemotherapy radiotherapy define standard . This study evaluate safety , toxicity maximal tolerate dose ( MTD ) everolimus association cisplatin pelvic radiotherapy , patient squamous cell carcinoma uterine cervix , stag IIB IIIB .</brief_summary>
	<brief_title>A Study mTOR Inhibitor Everolimus ( RAD001 ) Association With Cisplatin Radiotherapy Locally Advanced Cervix Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . ECOG performance 0 , 1 2 . 2 . Evidence measurable disease unidimensional form . 3 . Epidermoid carcinoma confirm histological examination cervix , stag IIB IIIB ( accord clinical radiological evaluation ) , without previous treatment . Absence positive paraaortic lymph node PET ( Positron Emission Tomography ) . 4 . Adequate function organ , accord follow criterion : 1 . Serum level aspartate aminotransferase ( ASAT/AAT/AST ) alanine aminotransferase ( ALT ) ≤2.5 x ULN ( Upper Limit Normal ) 2 . Total serum bilirubin ≤1.5 ULN 3 . Absolute neutrophils count ≥1.500/mm3 4 . Platelet count ≥100.000/mm3 5 . Hemoglobin ≥10.0 g/dL 6 . Serum calcium ≤12.0 mg/dL 7 . Serum creatinine ≤1.5 x ULN estimate creatinine clearance ( CockroftGault ) ≥60 mL/min 8 . Prothrombin time ≤1.5 x ULN Obs . : The serum level potassium , magnesium , sodium calcium outside normality range correct administration first dose investigational product . 5 . Patients least one measurable lesion baseline period , accord criterion RECIST , version 1.1 . 6 . Adequate lipid profile : total cholesterol &lt; 300 mg/dL triglyceride &lt; 200 mg/dL . 7 . Willingness follow treatment plan , schedule visit , laboratory radiological examination , well procedure . 8 . Signed date informed consent form , indicate patient ( his/her representative ) receive information relevant study aspect , his/her inclusion . Women possibility become pregnant present negative serum examination pregnancy , do within period 7 day administration study treatment ; willing use contraceptive method along entire study , 3 month last administration investigational drug . 1 . Major surgery &lt; 4 week study treatment start . 2 . Any malignant neoplasia last 5 year , except adequately treat melanoma skin cancer . 3 . Metastases initial diagnostic evaluation [ thorax abdomen computerize tomography ( contrast ) , pelvis magnetic resonance PET scan ] . 4 . Occurrence follow event , period 12 month previously study medication administration : unstable angina pectoris , symptomatic congestive heart failure ( II , III , IV NYHA ) , myocardium infarction , severe uncontrolled cardiac arrhythmia , cerebrovascular accident . 5 . Positive serology HIV infection . 6 . Patients positive examination hepatitis B ( HBsAg , antiHBs without previous vaccination HBV antiHBc ) hepatitis C ( HCV RNA detectable PCR ) . 7 . Any psychologic , familial , social geographic problem could embarrass adhesion protocol study scheme . 8 . Patients use agent investigation receive investigational medication ≤4 week study treatment start . 9 . Patients present severe and/or uncontrolled medical problem , disturbance could affect participation study , , instance : Unstable angina pectoris , symptomatic congestive heart failure ( II , III , IV NYHA ) , myocardial infarction ≤12 month first administration study medication , severe uncontrolled cardiac arrhythmia , cerebrovascular accident ≤12 month start study medication administration ; Severely compromise pulmonary function define spirometry 50 % anticipate normal value decompensated pulmonary disease . Uncontrolled diabetes satisfactorily define fast glycemia result &gt; 2.0 x ULN ; Any active uncontrolled disease/infection ( acute chronic ) compromise patient evaluation capability impede him/her complete study . Hepatic disease cirrhosis , decompensated hepatic disease , active chronic hepatitis , persistent chronic hepatitis . Compromising gastrointestinal ( GI ) function , GI disease could significantly alter everolimus absorption . 10 . Patients unwilling unable accomplish protocol requirement . 11 . Hypersensitivity everolimus excipients , rapamycins ( instance : sirolimus , temsirolimus ) . 12 . Patients receive systemic immunosuppressive agent chronically . Inhaling topic corticosteroid acceptable . The patient receive stable chronic ( increase within last month ) dose corticosteroid , maximal dose correspond 20 mg de prednisone 10 mg dexamethasone per day . Pregnant ( , positive examination beta human chorionic gonadotropin ) lactate woman . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cervical cancer ,</keyword>
	<keyword>radiotherapy ,</keyword>
	<keyword>chemotherapy ,</keyword>
	<keyword>rad001 ,</keyword>
	<keyword>everolimus</keyword>
</DOC>